Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has submitted an application for the listing of a long-acting hemophilia dual therapy this year.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) announced that its long-acting hemophilia A therapy, Mim8, has received positive interim results in the Phase 3 clinical trial FRONTIER3 for 1-11 year old children with hemophilia A (with and without inhibitors). The company expects to submit regulatory application for Mim8 in 2025. Mim8 is an investigational bispecific antibody that mimics factor VIIIa (FVIIIa) and is intended to provide sustained hemostatic effect for hemophilia A patients, for use in weekly, bi-weekly, or monthly prophylactic treatment regimens. Mim8 is administered via subcutaneous injection and works by bridging factor IXa and factor X, replacing factor VIII and restoring the body's ability to generate thrombin, helping blood to clot.